Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11768442 | 0.84 | MGLL (0.54) | CA12CA1CA9CA2KDM4E | |
| SCHEMBL8131868 | 0.84 | HSP90AA1 (0.57) | CHRM5CHRM3HSP90AA1PARK7CA12 | |
| SCHEMBL8317087 | 0.82 | ATM (0.58) | CHRM5CHRM3CA12CA1CA9 | |
| SCHEMBL14656875 | 0.79 | MGLL (0.69) | CHRM5CHRM3HSP90AA1PARK7CA12 | |
| SCHEMBL4415503 | 0.78 | CHRM5 (0.65) | CHRM5CHRM3HSP90AA1PARK7CA12 | |
| SCHEMBL12824609 | 0.78 | CHRM5 (0.60) | CHRM5CHRM3HSP90AA1PARK7CA12 | |
| SCHEMBL7558814 | 0.78 | CES2 (0.53) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL1270493 | 0.77 | CHRM5 (0.52) | CHRM5CHRM3HSP90AA1PARK7CA12 | |
| SCHEMBL127852 | 0.76 | PARK7 (0.55) | CHRM5CHRM3HSP90AA1PARK7CA12 | |
| SCHEMBL125865 | 0.75 | PARK7 (0.54) | CHRM5CHRM3HSP90AA1PARK7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3088397-B1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3088397-A1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2152692-B1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8084454-B2 | Cell cycle G2-checkpoint-abrogating 1-[(2-pyridyl)amino]-azoline-2,5-dione derivatives with at least one halogen group, to selectively sensitize cancer cells to DNA damaging reagents without additional anticarcinogenic treatment; cytolytic agents, antiproliferatives, apoptosis | CANBAS CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CDKN1A, CDC25C, DDB1 | CHRM5 4684/4885CHRM3 4765/4885HSP90AA1 2488/4885 |
| US-20080275057-A1 | Compounds with anti-cancer activity | CDKN1A, CDC25C, DDB1 | CHRM5 4684/4885CHRM3 4765/4885HSP90AA1 2488/4885 |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | MAVS, DDX18, ZC3HAV1 | CHRM5 4829/4885CHRM3 4854/4885HSP90AA1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.